Skip to content

IBD and Cannabinoid Medicine

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A with one of their gastroenterologists on the subject. 

People suffering from IBD often have symptoms that can easily interfere with life’s daily activities.  Those symptoms include:

  • Abdominal cramps and pain
  • Diarrhea that may be bloody
  • Severe urgency to have a bowel movement
  • Fever
  • Weight loss
  • Loss of appetite
  • Iron deficiency anemia due to blood loss

With many states that allow medical marijuana including IBD in their ‘qualifying conditions’ list, patients have been able to use cannabinoid medicine in conjunction with their traditional treatment to find symptom relief.  Our data at Arfinn Med indicates that patients adding cannabinoid treatment to their regiment have seen an improvement in their symptoms, indicating a 3.9 out of 5.0 on our symptom relief scale.

A screenshot of a cell phone

Description automatically generated

If you are suffering from IBD and are interested in learning more about cannabinoid medicine, please reach out to your physician to discuss ways of incorporating it into your existing treatment. If your physician would like more information, please refer them to Arfinn Med and its EMR and data portal focusing on complimentary and alternative medicines (CAM).

Resources:

https://healthblog.uofmhealth.org/digestive-health/cannabis-for-treating-ibd-hope-or-hype

https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-syndrome#1

https://www.healthline.com/health/crohns-disease/facts-statistics-infographic#1

Stories you may be interested in

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More

How Medical Marijuana Affects Men vs. Women

As expected, men and women differ in a multitude of ways, from genetic makeup and hormonal behavior to how we process information and emotionally respond. The differences in our makeup are the exact reason why any medical treatment, including medical marijuana, will have a diverse impact on men vs. women. Let’s take a closer look…
Read More

New Feature: Text Message Treatment Updates

New to the Arfinn Med portal comes the ability to receive real time updates from patients via text messaging. This new addition will allow physicians to stay up to date on current patient efficacies as well as streamline the data collection process. Through the new text messaging function, physicians are able to send patients automated…
Read More

European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana

Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More

Cannabis for Treating IBD: Hope or Hype?

Nausea, abdominal pain and changes in appetite. These are all things that can significantly impact one’s wellbeing if left untreated, yet they have all shown marked improvements when associated with cannabis. Yet, less is known about the effects of cannabis on inflammatory bowel disease, or IBD, a chronic inflammatory condition that impacts the gastrointestinal tract…
Read More

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More

Leave a Comment

You must be logged in to post a comment.